Thermo Fisher Scientific, which sells equipment, software, and services for scientific research, had a stellar 2020, lifted by huge demand for its products, such as PCR tests, during the pandemic. The lab supplier collected $6.6 billion in revenue during the year from sales of instruments and other products to more than 200 customers trying to develop COVID-19 vaccines and treatments. Overall revenue rose 26% to $32 billion, compared with the prior year, while profits soared 73% to $6.4 billion. Even with the COVID vaccine rush behind them, the company is thinking big with its $17.4 billion acquisition of contract research business PPD, which it announced in April.
Lists ranking Thermo Fisher Scientific
World’s Most Admired Companies - 2021After a year in which humanity leaned more heavily...READ MOREview in list
Latest news for Thermo Fisher Scientific
- HealthWhy the Companies That Actually Make Your Drugs Are in a Merger FrenzyMay 15, 2017 5:46 PM UTC
- HealthAffymetrix Rejects Rival Bid, Supports Thermo Fisher MergerMarch 21, 2016 1:14 AM UTC